As a 2024 Schmidt Science Fellow, Wonjun plans to develop novel nanosensors for early-stage cancer diagnostics in a clinical setting.
Early-stage cancer diagnostics pose significant challenges due to the short half-life of biomarkers, sample dilution, and the small size of tumors.
Nanosensors capable of detecting target biomarkers with high sensitivity and selectivity hold great promise. This work aims to integrate nanotechnology with medical devices to enable 3D biomedical chemical imaging.
The nanosensor-enabled early-stage cancer diagnostics has the potential to make a positive impact on healthcare.